Synspira raises $8m for inhaled pulmonary therapies

Privately-held Synspira said today that raised $8 million from an unnamed private investor to bring its inhaled cystic fibrosis therapy into a Phase I safety study.

The Boston-based company was founded earlier this year and is focused on developing inhaled therapies for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. Synspira holds an exclusive field license to Synedgen’s Glycomics Technology platform and its pulmonary delivery assets.

Get the full story at our sister site, Drug Delivery Business News.

The post Synspira raises $8m for inhaled pulmonary therapies appeared first on MassDevice.

from MassDevice http://ift.tt/2sl6MHF